• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

June 11, 2018
Company Drug/Device Medical Condition Status
Peloton Therapeutics, Inc. PT2977 (oral HIF-2α inhibitor) Treatment of von Hippel-Linau (VHL) disease-associated kidney cancer Phase II trial initiated enrolling 50 subjects in the U.S.
Viking Therapeutics, Inc. VK2809 Primary hypercholesterolemia and non-alcoholic fatty liver desease (NAFLD) Phase II trial initiated
Tricida, Inc. TRCA-301 chronic kidney disease patients with metabolic acidosis Phase III trial initiated enrolling 217 subjects in the U.S. and Europe
Janssen (part of Johnson & Johnson) esketamine nasal spray adults with treatment-resistant depression Phase III trial initiated
Camber Spine Technologies ENZA (Titanium Anterior Lumbar Interbody Fusion (ALIF) system autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1 510(k) clearance granted by the FDA
Royal Philips Ingenia Elition 3.0T MR solution increased diagnostic performance 510(k) clearance granted by the FDA
Partner Therapeutics, Inc. Leukine adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrom of Acute Radiation Syndrome) Approval granted by the FDA
Mylan Fulphila (pegfilgrastim-jmbd) febrile neutropenia Approval granted by the FDA
Eli Lilly and Incyte Corporation OLUMIANT (baricitnib) adults with moderately-to-severely active Rheumatoid Arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitor therapies Approval granted by the FDA
Micronics, Inc. PanNAT STEC Test Shiga toxin-producing E. Coli (STEC) Clearance granted by the FDA
Chugai Pharmaceutical Co., Ltd. HEMLIBRA (U.S. generic name: emicizumab-kxwh) adults and children with hemophilia A without factor VIII inhibitors Priority Review Designation granted by the FDA
Pfizer Talazoparib germline (inherited) BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer (MBC) Priority Review Designation granted by the FDA
Pfizer Xalkori (crizotinib) relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive Breakthrough Therapy Designation granted by the FDA
AutoGenomics, Inc. INFINITI Neutral Response Panel opioid dependency Breakthrough Device Designation granted by the FDA
Curis, Inc. fimepinostat (CUDC-907) relapsed or fractory (R/R) diffuse large B-cell lymphoma (DLBCL) Fast Track Designation granted by the FDA
Alnylam Pharmaceuticals, Inc. ALN-TTRsc02 Transthyretin-mediated amyloidosis Orphan Drug Designation granted by the FDA

Upcoming Events

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing